Verisante launches rapid Raman spectroscopy system for cancer research, other markets

Cancer detection technology developer Verisante has launched its VRS rapid Raman spectroscopy system designed for skin and lung cancer detection and research, among other research areas.

Cancer detection technology developer Verisante (Vancouver, BC, Canada) has launched its VRS rapid Raman spectroscopy system designed for skin and lung cancer detection and research, among other research areas.

Related: Verisante, Clarion Medical Technologies enter distribution agreement

Related: Biophotonics enables early and accurate cancer diagnosis

The system, which can acquire Raman spectra in <1 s, features the same technology used in the company's Aura system, which noninvasively and biochemically analyzes the skin quickly to evaluate skin lesions that may be clinically suspicious for melanoma, squamous cell carcinoma, and basal cell carcinoma. Used prior to making a decision to biopsy, the device helps to automate the current process of diagnosis, allowing rapid scanning of 20 to 40 skin lesions on at-risk individuals.

The company is displaying the VRS system at SPIE Photonics West 2014, taking place February 4–6, 2014, in San Francisco, CA.

-----

Follow us on Twitter, 'like' us on Facebook, and join our group on LinkedIn

Subscribe now to BioOptics World magazine; it's free!

More in Spectroscopy